{"id":"fludarabine-injection","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Infection"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Fever"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Neurotoxicity"},{"rate":"5-15","effect":"Tumor lysis syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fludarabine is a fluorinated nucleoside analog that is phosphorylated intracellularly to its active form, fludarabine triphosphate. This active metabolite inhibits both ribonucleotide reductase and DNA polymerase, preventing DNA synthesis and repair. The drug is particularly effective against lymphoid malignancies because lymphocytes have high levels of deoxycytidine kinase, the enzyme responsible for its activation.","oneSentence":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:51.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Non-Hodgkin's lymphoma"},{"name":"Acute leukemias"}]},"trialDetails":[{"nctId":"NCT05702853","phase":"PHASE1, PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":"Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT07490275","phase":"PHASE1","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy","enrollment":9},{"nctId":"NCT07491263","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-05-01","conditions":"Relapsed/Refractory CD19-positive B-ALL","enrollment":6},{"nctId":"NCT07490041","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-03-19","conditions":"Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE)","enrollment":36},{"nctId":"NCT07487402","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-03-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":27},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT05780879","phase":"PHASE2","title":"A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-06-03","conditions":"Secondary Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06658951","phase":"NA","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"UTC Therapeutics Inc.","startDate":"2025-04-03","conditions":"HER2-positive Advanced Malignant Solid Tumors","enrollment":30},{"nctId":"NCT06481735","phase":"PHASE1, PHASE2","title":"TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-02-15","conditions":"Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT07453446","phase":"PHASE1","title":"Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma","status":"RECRUITING","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","startDate":"2025-03-04","conditions":"Relapsed or Refractory Lymphoma","enrollment":18},{"nctId":"NCT07275736","phase":"EARLY_PHASE1","title":"A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases","status":"RECRUITING","sponsor":"Juventas Cell Therapy Ltd.","startDate":"2025-03-01","conditions":"Neurological Autoimmune Diseases","enrollment":18},{"nctId":"NCT05617625","phase":"PHASE2","title":"CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome","status":"SUSPENDED","sponsor":"Guenther Koehne","startDate":"2026-06","conditions":"Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease","enrollment":50},{"nctId":"NCT07447726","phase":"PHASE1, PHASE2","title":"Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-05","conditions":"Large B-Cell Lymphoma (LBCL)","enrollment":3},{"nctId":"NCT07416682","phase":"EARLY_PHASE1","title":"CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2026-01-31","conditions":"High-risk Plasma Cell Neoplasms","enrollment":20},{"nctId":"NCT07246096","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-02-20","conditions":"Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis","enrollment":60},{"nctId":"NCT05672459","phase":"PHASE1, PHASE2","title":"A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-06-21","conditions":"Solid Tumor","enrollment":31},{"nctId":"NCT07428486","phase":"PHASE1","title":"A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-17","conditions":"Phase I, FLAG Chemotherapy, Lisaftoclax","enrollment":24},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT07421856","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2026-02-01","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma Refractory","enrollment":24},{"nctId":"NCT06253520","phase":"PHASE1","title":"Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-16","conditions":"Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer","enrollment":210},{"nctId":"NCT07406984","phase":"PHASE1","title":"Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Beijing Immunochina Medical Science & Technology Co., Ltd.","startDate":"2026-03-05","conditions":"Adenocarcinoma of Gastric, Adenocarcinoma of Esophagogastric Junction","enrollment":18},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT07406724","phase":"PHASE2","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2026-02-26","conditions":"Melanoma (Excluding Uveal Melanoma)","enrollment":90},{"nctId":"NCT05739409","phase":"NA","title":"LILRB4 STAR-T Cell Therapy for Monocytic Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-16","conditions":"Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia","enrollment":1},{"nctId":"NCT03182244","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2017-10-25","conditions":"AML With FLT3 Mutation","enrollment":276},{"nctId":"NCT07283315","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2025-12-03","conditions":"Paediatric B Cell-related Autoimmune Diseases, Autoimmune Diseases, CAR","enrollment":12},{"nctId":"NCT06549296","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases","status":"SUSPENDED","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2024-09-13","conditions":"Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis","enrollment":12},{"nctId":"NCT06775912","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases","status":"RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2025-01-03","conditions":"SLE, Systemic Sclerosis, IIM","enrollment":18},{"nctId":"NCT07011004","phase":"PHASE1","title":"A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-30","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT06462144","phase":"EARLY_PHASE1","title":"IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy","status":"TERMINATED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-06-13","conditions":"Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM)","enrollment":3},{"nctId":"NCT07367685","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Fujian Medical University","startDate":"2026-05-01","conditions":"Recurrent/Refractory B-cell Lymphoma","enrollment":6},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT07366658","phase":"PHASE1","title":"Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-20","conditions":"SCLC, Extensive Stage, Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT00902044","phase":"PHASE1","title":"Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2010-02-11","conditions":"Sarcoma","enrollment":36},{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT03642626","phase":"PHASE2","title":"MT2017-45: CAR-T Cell Therapy for Heme Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-12-18","conditions":"Acute Lymphoblastic Leukemia, Large B-cell Lymphoma","enrollment":150},{"nctId":"NCT07337785","phase":"EARLY_PHASE1","title":"CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases","status":"RECRUITING","sponsor":"Daishi Tian","startDate":"2025-12-12","conditions":"Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":36},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT05868915","phase":"PHASE1","title":"HV-101 for Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hervor Therapeutics","startDate":"2023-08-04","conditions":"Advanced Solid Tumors","enrollment":1},{"nctId":"NCT06663046","phase":"EARLY_PHASE1","title":"Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Wondercel Biotech (ShenZhen)","startDate":"2025-07-01","conditions":"Multiple Myleoma, Refractory and Relapsed Multiple Myeloma","enrollment":30},{"nctId":"NCT06653023","phase":"EARLY_PHASE1","title":"Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer","status":"RECRUITING","sponsor":"Wondercel Biotech (ShenZhen)","startDate":"2024-10-23","conditions":"HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":60},{"nctId":"NCT06662227","phase":"EARLY_PHASE1","title":"Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors","status":"RECRUITING","sponsor":"Wondercel Biotech (ShenZhen)","startDate":"2024-10-24","conditions":"B Cell Lymphoma, B Cell Leukemia, B Cell Malignancy","enrollment":30},{"nctId":"NCT07342738","phase":"EARLY_PHASE1","title":"TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"KRAS G12V, KRAS G12D, Solid Tumor","enrollment":25},{"nctId":"NCT05183035","phase":"PHASE3","title":"Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"PedAL BCU, LLC","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia","enrollment":98},{"nctId":"NCT05634785","phase":"PHASE2","title":"CD30 CAR for CD30+ NSGCT","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-12-09","conditions":"Germ Cell Tumor, Nonseminomatous Germ Cell Tumor","enrollment":2},{"nctId":"NCT06898385","phase":"PHASE1","title":"A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-03-27","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT06514768","phase":"EARLY_PHASE1","title":"JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","startDate":"2024-06-20","conditions":"B-cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":20},{"nctId":"NCT04240002","phase":"PHASE1, PHASE2","title":"A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-09-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)","enrollment":9},{"nctId":"NCT07315503","phase":"EARLY_PHASE1","title":"An Open-label Study of GC012F in Rheumatoid Arthritis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-15","conditions":"Rheumatoid Arthritis","enrollment":9},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT06626256","phase":"PHASE1","title":"STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2025-12-05","conditions":"Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm","enrollment":""},{"nctId":"NCT07301164","phase":"EARLY_PHASE1","title":"Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-12-11","conditions":"System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis","enrollment":10},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT05115630","phase":"PHASE2","title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-08","conditions":"Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT06546150","phase":"PHASE1","title":"RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-03-01","conditions":"KRAS G12D, T Cell Therapy","enrollment":30},{"nctId":"NCT07153068","phase":"PHASE1, PHASE2","title":"SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)","enrollment":12},{"nctId":"NCT03696784","phase":"PHASE1","title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Lymphoma, Lymphoma, B-Cell, Immune System Diseases","enrollment":19},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT07265206","phase":"EARLY_PHASE1","title":"A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Juventas Cell Therapy Ltd.","startDate":"2025-12-30","conditions":"Neurological Autoimmune Diseases","enrollment":15},{"nctId":"NCT06001788","phase":"PHASE1","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2024-02-22","conditions":"AML, AML With Mutated NPM1, Hematologic Malignancy","enrollment":171},{"nctId":"NCT06515314","phase":"PHASE1","title":"HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Ruiliyuan Biotechnology Co., Ltd.","startDate":"2024-10-17","conditions":"Hepatic Cell Carcinoma","enrollment":12},{"nctId":"NCT07259070","phase":"PHASE1, PHASE2","title":"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-11-29","conditions":"DLBCL, CLL, FL","enrollment":20},{"nctId":"NCT02379520","phase":"PHASE1","title":"HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-09","conditions":"Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma","enrollment":32},{"nctId":"NCT07139509","phase":"PHASE1","title":"Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Xi'an No.3 Hospital","startDate":"2024-10-03","conditions":"Relapsed/Refractory Multiple Myeloma(MM)","enrollment":18},{"nctId":"NCT07240857","phase":"EARLY_PHASE1","title":"A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-12-31","conditions":"Castration-Resistant Prostate Cancer (CRPC)","enrollment":18},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT00881920","phase":"PHASE1","title":"Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Lymphoma, Myeloma, Leukemia","enrollment":54},{"nctId":"NCT00801489","phase":"PHASE2","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-04","conditions":"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":270},{"nctId":"NCT06315309","phase":"PHASE2","title":"Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-15","conditions":"GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes","enrollment":29},{"nctId":"NCT07203404","phase":"EARLY_PHASE1","title":"A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.","status":"RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2025-07-24","conditions":"SLE, LN, ANCA Associated Vasculitis","enrollment":84},{"nctId":"NCT04756648","phase":"PHASE1","title":"Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhejiang University","startDate":"2021-03-10","conditions":"Advanced Hepatocellular Carcinoma","enrollment":21},{"nctId":"NCT04083495","phase":"PHASE2","title":"CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-17","conditions":"Peripheral T Cell Lymphoma","enrollment":20},{"nctId":"NCT07091370","phase":"PHASE1","title":"Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy","status":"NOT_YET_RECRUITING","sponsor":"Juventas Cell Therapy Ltd.","startDate":"2025-12-27","conditions":"AIHA - Cold Autoimmune Hemolytic Anemia","enrollment":12},{"nctId":"NCT04697940","phase":"PHASE1, PHASE2","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han weidong","startDate":"2021-04-15","conditions":"Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells","enrollment":33},{"nctId":"NCT03672318","phase":"PHASE1","title":"Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-01-14","conditions":"Multiple Myeloma, Immune System Diseases","enrollment":25},{"nctId":"NCT05712278","phase":"PHASE1","title":"A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2023-06-16","conditions":"Acute Myeloid Leukaemia","enrollment":7},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT05438667","phase":"EARLY_PHASE1","title":"TCR-T Cell Therapy on Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Pancreatic Cancer","enrollment":18},{"nctId":"NCT07148791","phase":"PHASE2","title":"Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-09-05","conditions":"IgG4 Related Disease, B-cell Mediated Autoimmune Disorders","enrollment":9},{"nctId":"NCT07109518","phase":"PHASE1","title":"uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT06986434","phase":"EARLY_PHASE1","title":"CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2025-08-26","conditions":"Relapsed or Refractory Plasma Cell Neoplasms","enrollment":20},{"nctId":"NCT03240731","phase":"PHASE2","title":"HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2017-08-10","conditions":"Sickle Cell Disease","enrollment":25},{"nctId":"NCT06464679","phase":"PHASE1","title":"An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-06-27","conditions":"Autoimmune Diseases","enrollment":72},{"nctId":"NCT07144462","phase":"EARLY_PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Neukio Biotherapeutics (Shanghai) Co., Ltd.","startDate":"2025-09-04","conditions":"Autoimmune","enrollment":8},{"nctId":"NCT07142161","phase":"EARLY_PHASE1","title":"A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2025-07-20","conditions":"Type 1 Diabetes","enrollment":3},{"nctId":"NCT07139067","phase":"PHASE1","title":"Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Peking University","startDate":"2025-04-27","conditions":"Advanced Solid Tumor Cancer","enrollment":10},{"nctId":"NCT06446128","phase":"EARLY_PHASE1","title":"A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)","status":"RECRUITING","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","startDate":"2024-05-07","conditions":"Non-Hodgkin Lymphoma, B-cell","enrollment":20},{"nctId":"NCT07105176","phase":"PHASE1","title":"HS-IT101 Injection for Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2025-08-30","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT05913804","phase":"PHASE1","title":"YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-06-28","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":12},{"nctId":"NCT07123545","phase":"PHASE1, PHASE2","title":"Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-08-01","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":20},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT07120607","phase":"PHASE1","title":"Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-18","conditions":"Leukemia","enrollment":9},{"nctId":"NCT05020015","phase":"PHASE2","title":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-11-12","conditions":"Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","enrollment":27},{"nctId":"NCT04684147","phase":"PHASE2","title":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Juventas Cell Therapy Ltd.","startDate":"2020-12-24","conditions":"Relapsed or Refractory Acute Lymphoblastic Leukemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CORNEAL EPITHELIUM DEFECT"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"HEPATIC ENCEPHALOPATHY"},{"count":1,"reaction":"LUNG INFECTION"},{"count":1,"reaction":"LUNG INFILTRATION"},{"count":1,"reaction":"OPTIC NEURITIS"},{"count":1,"reaction":"PLASMA CELL MYELOMA"},{"count":1,"reaction":"THROMBOTIC MICROANGIOPATHY"},{"count":1,"reaction":"VISION BLURRED"}],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fludara"],"phase":"phase_3","status":"active","brandName":"Fludarabine Injection","genericName":"Fludarabine Injection","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells. Used for Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma, Acute leukemias.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}